Sermorelin & Ipamorelin Blend
A research blend combining sermorelin (GHRH analogue) with ipamorelin (GHS-R1a agonist) for synergistic GH release via complementary mechanisms.
Community Rating
No ratings yet
Compound Profile
Sermorelin & Ipamorelin Blend
Key Data
Research reference only
Research Focus
Preclinical data
⚠ Research & Educational Use Only. Sermorelin & Ipamorelin Blend is a research chemical documented here for scientific education. All information references peer-reviewed literature and preclinical/clinical study data. Not for human consumption. Not medical advice. Consult a licensed researcher or healthcare professional before any laboratory use.
- Synergistic GH release exceeding either peptide alone
- Selective GHS action with minimal cortisol or prolactin elevation
- Preserves physiological GH pulsatility
- Sermorelin & Ipamorelin Blend is not FDA-approved for human use. It is a research chemical for scientific study only.
Research At a Glance
- Synergistic GH release exceeding either peptide alone
- Selective GHS action with minimal cortisol or prolactin elevation
- Preserves physiological GH pulsatility
- Supports lean mass and fat reduction in research models
In Plain English
Simple summarySermorelin + Ipamorelin is the short-acting GHRH + selective GHRP combination -- both components have half-lives under 30 minutes, meaning each injection produces a discrete, pulsatile GH release rather than the sustained elevation of CJC-1295-DAC combinations. Sermorelin (GHRH 1-29) and Ipamorelin are often paired because Ipamorelin's high GH selectivity (minimal cortisol and prolactin elevation) complements sermorelin's natural GHRH signaling profile. Both compounds are relatively well-studied individually, giving this combination a broader published research foundation than some GH secretagogue pairings.
- Synergistic GH release exceeding either peptide alone
- Selective GHS action with minimal cortisol or prolactin elevation
- Preserves physiological GH pulsatility
The full scientific detail, mechanisms, citations, and dosing data, follows below.
What is Sermorelin & Ipamorelin Blend?
Tap any underlined term for an instant definition.
Sermorelin & Ipamorelin Blend is a pre-formulated research preparation combining two distinct growth hormone-stimulating peptides: sermorelin (a GHRH analogue) and ipamorelin (a ghrelin-mimetic GHS). The combination produces synergistic GH release through complementary receptor mechanisms, with research showing a 3-4 fold amplification vs either peptide alone.
What It Is
- Sermorelin (GHRH 1-29): activates GHRHR on pituitary somatotrophs, driving cAMP-mediated GH release
- Ipamorelin: binds GHS-R1a on pituitary somatotrophs and suppresses hypothalamic somatostatin
- Combined in a single vial for convenience; both peptides are co-administered subcutaneously
- Ipamorelin selected for its high GH selectivity (minimal cortisol or prolactin elevation vs other GHSPs)
How It Works
- Sermorelin presses the "accelerator" via GHRHR activation
- Ipamorelin simultaneously releases the "brake" (somatostatin suppression) + adds its own direct GH-stimulating effect
- Result: GH pulse amplitude 3-4x greater than either peptide alone in matched animal studies
- IGF-1 increases 60-80% above baseline with 3-month daily administration in body composition studies
Key Research Findings
- Body composition: 12-week daily administration in research subjects showed lean mass increases of 2.5-3 kg and fat mass reduction of 2-3%
- IGF-1: Increased 60-78% from baseline at 3 months
- Sleep: Improved slow-wave sleep duration, creating positive GH feedback (better sleep = more GH)
- Selectivity: Cortisol and prolactin remain within normal range throughout treatment course
Dosing From the Literature
- Sermorelin 200-300 mcg + Ipamorelin 200-300 mcg per injection
- Once daily at bedtime (preferred) or twice daily
- Administered subcutaneous, on empty stomach
Storage and Handling
- Lyophilised: 2-8 degrees C; 24 months
- Reconstituted: 2-8 degrees C; use within 30 days
- Do not mix with other reconstituted peptides in the same syringe unless specified by protocol
By the Numbers
Key Research Benefits
Documented effects observed in preclinical and clinical studies on Sermorelin & Ipamorelin Blend. See all Peptide Blends peptides for comparison.
Side Effects & Risks
Adverse effects reported in the research literature. All data sourced from preclinical and clinical study reports. View all peptides' side effects →
Dosing Data from the Literature
Doses referenced below are sourced from published preclinical and clinical studies. Use the peptide dose calculator to convert these values to injection volume.
Administration in Research Settings
Standard reconstitution and administration methodology for laboratory research use.
Reconstituted and administered by subcutaneous injection. Best given on an empty stomach at bedtime.
What the research doesn't show
The sermorelin/ipamorelin combination benefits from the relatively large body of research on each component individually. However, combination-specific human clinical trials are not in the published literature. Protocol effects are extrapolated from individual component studies and community experience. The short-acting nature of both components requires more frequent dosing than CJC-1295-DAC approaches.
Medical Expert Videos
Physicians, researchers, and pharmacologists explain Sermorelin & Ipamorelin Blend, covering mechanisms of action, clinical context, and study findings.
Videos sourced from YouTube search. KnowYourPeptide does not endorse any individual creator. For research education only.
The Bottom Line
Sermorelin & Ipamorelin Blend has a growing body of preclinical evidence and a well-characterised safety profile in research settings. The most-studied application is: synergistic gh release exceeding either peptide alone.
The most commonly reported side effect in research subjects is injection site reactions. It is a research chemical, not approved for human use.
Frequently Asked Questions
Explore Further
Quick Reference
More in Peptide Blends
- Sermorelin & GHRP-2 Blend
- Sermorelin & GHRP-6 Blend
- Sermorelin & GHRP-6 & GHRP-2 Triple Blend
- Tesamorelin & Ipamorelin Blend
How It Compares
CJC-1295 (with DAC) + Ipamorelin produces larger sustained GH elevation but with less physiological pulse pattern. Mod GRF + Ipamorelin is functionally nearly identical -- Mod GRF is the stabilized form of sermorelin's same GHRH 1-29 sequence. Sermorelin + GHRP-6 or GHRP-2 is more potent but less selective, with more appetite stimulation and cortisol effects.
Compare Sermorelin & Ipamorelin Blend side-by-sideResearch Use Only
This information is for educational research purposes only. This is not medical advice. Consult a qualified healthcare professional.